These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11858906)

  • 1. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.
    Goldstein EJ; Citron DM; Vreni Merriam C; Tyrrell K; Warren Y
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2726-30. PubMed ID: 10543754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2363-7. PubMed ID: 11451698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrel KL; Fernandez H
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1963-7. PubMed ID: 12760875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
    Goldstein EJ
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3008-11. PubMed ID: 12937015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV
    Antimicrob Agents Chemother; 1999 Mar; 43(3):705-7. PubMed ID: 10049296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.
    Kleinkauf N; Ackermann G; Schaumann R; Rodloff AC
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1896-9. PubMed ID: 11353648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis.
    Puglisi S; Privitera S; Maiolino L; Serra A; Garotta M; Blandino G; Speciale A
    J Med Microbiol; 2011 Sep; 60(Pt 9):1353-1359. PubMed ID: 21498651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    J Antimicrob Chemother; 2002 Sep; 50(3):411-20. PubMed ID: 12205068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
    Wexler HM; Molitoris E; Molitoris D; Finegold SM
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
    Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
    J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
    Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA
    J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW; Osmolski JR
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.
    Duffy LB; Crabb D; Searcey K; Kempf MC
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():29-33. PubMed ID: 10824029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
    Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.